FDA Approves Moderna's RSV Vaccine for Adults Under 60 Amid Industry Uncertainty
The FDA has expanded Moderna's RSV vaccine approval to include adults under 60 at increased risk, pending CDC advisory committee approval, marking a significant step in protecting more vulnerable populations from severe RSV illness.